Business context and reporting period
This is Transgenomic, Inc.’s Form 10-K for the fiscal year ended December 31, 2011, filed March 14, 2012. Although the request identifies Precipio, Inc., the filing itself is for Transgenomic, Inc.; the filing text does not explain that difference. The company operated clinical laboratories, pharmacogenomics research services, and diagnostic tools businesses.
Financial results and liquidity
| Metric | 2011 | 2010 |
|---|---|---|
| Revenue | $31.971 million | $20.048 million |
| Gross profit / margin | $18.437 million / 58% | $9.764 million / 49% |
| Operating loss | $2.972 million | $3.612 million |
| Net loss | $9.782 million | $3.134 million |
| Net loss attributable to common stockholders | $10.792 million | $3.134 million |
| Basic and diluted loss per share | $0.22 | $0.06 |
| Cash from operating activities | $0.220 million | $(1.718) million |
At year-end, cash was $4.946 million, working capital was $0.870 million, and total assets were $33.562 million. Total debt was $11.722 million, including $3.082 million of short-term debt, $3.703 million of current maturities of long-term debt, and $4.937 million of long-term debt. Contractual obligations totaled $21.965 million, including debt, interest, leases, and purchase commitments.
Material changes versus prior period
- Revenue increased 59%, principally because the FAMILION genetic-testing business acquired in December 2010 contributed $11.1 million of 2011 revenue. Clinical Laboratories revenue rose to $16.038 million from $3.606 million; Pharmacogenomics Services rose to $2.280 million from $1.373 million.
- Diagnostic Tools revenue declined 9% to $13.653 million. WAVE System sales fell to 13 from 25, amid competitive pressure; OEM instrument sales increased to 14 from 10.
- Gross margin improved to 58% from 49%. Operating loss narrowed, but net loss widened because of $6.066 million of preferred-stock and warrant expense, primarily a non-cash fair-value charge, and higher interest expense.
- SG&A increased to $19.150 million from $10.933 million, including acquired-business expenses, acquired-intangible amortization, stock-based compensation, and $1.7 million of bad-debt expense.
- Fourth-quarter 2011 revenue was $8.571 million versus $5.092 million in fourth-quarter 2010; reported quarterly net income was $0.264 million versus a $0.767 million loss.
Outlook, commentary, and risks
Management anticipated continued growth in all three business units during 2012, citing new assays and tests, the FAMILION franchise, and commercialization of ICE COLD-PCR and other mutation-detection technologies. The filing provides no specific numerical revenue or earnings guidance. Management stated that year-end liquidity plus proceeds from the February 2012 financing should meet expected cash needs for the foreseeable future.
In February 2012, the company raised approximately $19.0 million gross by issuing 19 million common shares at $1.00 per share and warrants for up to 9.5 million shares at $1.25. The $3.0 million December 2011 convertible notes converted in that financing into 3 million shares and warrants for 1.5 million shares. The company reported approximately $17.5 million of financing proceeds after costs.
- Risks include a history of operating losses, the need for external funding, reimbursement and payer-mix pressure, competitive challenges to WAVE sales, and variable project-based research revenue.
- The company relied on a single supplier for key WAVE instrument modules and did not hedge foreign-currency exposure.
- Clinical laboratory operations depend on continued CLIA compliance and are subject to HIPAA and other healthcare regulation. Patent and other intellectual-property disputes, acquisition integration, and potential dilution from securities issuance are additional risks.
- Management said ordinary-course legal claims were not expected to have a material adverse effect. The independent auditor gave an unqualified opinion and reported effective internal control over financial reporting.
Most important facts for investors to verify
- Confirm the issuer identity: this filing is for Transgenomic, Inc., not Precipio, Inc.
- Review the February 2012 financing terms, net proceeds, registration-statement obligations, warrant overhang, and dilution alongside the post-financing share count.
- Assess debt repayment and interest requirements, including secured PGxHealth notes and the timing and terms of the Third Security note conversion.
- Evaluate whether FAMILION-driven growth and improved gross margins can persist, given the decline in Diagnostic Tools sales and higher bad-debt expense.
- Track receivable quality, reimbursement trends, and quarterly volatility in pharmacogenomics project revenue.